Home Your basket
• Bone-Anchored Hearing Aid...
   Price 10.50 €
• Early evaluation of voice...
   Price 12.00 €
• Reconstruction of a trans...
   Price 8.50 €
• Navigation in head and ne...
   Price 10.50 €
• The rehabilitation of the...
   Price 10.50 €
• Autologous fat graft for ...
   Price 14.00 €
• Amphicrine adenoma of the...
   Price 8.50 €
• Progressive cochleo-vesti...
   Price 5.50 €
• Endoscopic scale for eval...
   Price 8.50 €
• Reconstruction after tumo...
   Price 10.50 €
• Influence of phonetic con...
   Price 10.50 €
• Necrotizing external otit...
   Price 10.50 €
• The value of fine-needle ...
   Price 10.50 €
• Cervico facial lymphangio...
   Price 10.50 €
• The role of larynx kinest...
   Price 10.50 €
• Ethmoidal metastasis reve...
   Price 8.50 €
• A survey of current wound...
   Price 5.50 €
• Desmoplastic ameloblastom...
   Price 5.50 €
• Hygiene and sterilisation...
   Price 10.50 €
• Evolution of facial nerve...
   Price 10.50 €
• Benign tumors of the nasa...
   Price 14.00 €
• Laryngeal paraganglioma m...
   Price 8.50 €
• ...
   Price 5.50 €
• Artistic anatomy of the n...
   Price 8.50 €
• Prognostic value of senti...
   Price 10.50 €
• Pharyngeal pouch surgery ...
   Price 5.50 €
• Characteristics of the co...
   Price 8.50 €
• Facial aesthetic lipostru...
   Price 10.50 €
• Unsteadiness and drunkenn...
   Price 10.50 €

Total Order 274.00 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 4 - 2003 o

SALIVARY GLANDS

Adenoid cystic carcinoma of the head and neck: A review of 30 cases


Authors : F. Raux-Rakotomalala, Th. Houliat, J. Martel, D. Stoll, J. P. Bébéar, V. Darrouzet (Bordeaux)

Ref. : Rev Laryngol Otol Rhinol. 2003;124,4:235-241.

Article published in french
Downloadable PDF document french



Summary : Objectives: To evaluate treatment results and identify pronostics factors which determine local and regional treatment failure and crude survival in adenoid cystic tumours (ACT) in the head and neck. Methods: A retrospective study (1984 to 2001) of 30 cases of adenoid cystic tumour. The mean age was 56.9 years, with a sex ratio female to male of 2:1. Tumours of all sites were encountered, most (26.7%) being in the nose and sinuses and major salivary glands (26.6%). Tumours at the T4 stage were found in 14 cases, mainly situated in the nose and sinuses (50%). No patient had cervical lymphadenopathy, while two patients (6.7%) had bony metastases at the time of diagnosis. Two patients (6.7%) were treated by surgery alone, for T1 and T2 tumours; four patients (13%) had radiotherapy alone, and 24 patients (80%) had surgery with post-operative radiotherapy with a mean dose of 60.3 Grays (56-65 Grays). Results: local recurrence occurred in 30.8% (nine cases) after a mean interval of 43 months (1 to 10 years). Treatment of these recurrences was by revision surgery in six cases, leading to local control in one case, but in a patient with pulmonary metastases. No cases of lymph node recurrence were observed. 30% of patients developed metastases; these were pulmonary in 44% and bony in 33.3%. Mean follow-up was five years. Crude survival at 3 years was 91%, at 5 years 86%, and at 10 years 50%. The percentage tumour-free survival was 70% at 3 years, and 57% at 5 Years. 22 patients (73.3%) are still alive, 17 of them recurrence-free. Analysis of the prognostic factors has shown tumour to be more aggressive in the nose and sinuses when they presented at an advanced stage (T4); recurrence was more common when excision was incomplete, or if there was peri-neural spread. Tumours of "massive" histological type carried a poorer prognosis than those of cribrigorm type (60% death compared with 10%). The development of metastases is independent of local recurrence. Metastases to bone appear to be more rapidly aggressive than pulmonary metastases, which may remain asymptomatic for some time. Conclusion: Combined radiotherapy and surgery have allowed improved local control of ACT, but the therapeutic challenge remains the multiply recurrent ACT, or those with symptomatic metastases, and this despite new research techniques (neutral therapy, immuno-histochemistry, molecular biology). ACT are rare tumours, whose prognosis remains poor.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE